Bli medlem
Bli medlem

Du är här

2016-05-17

Peptonic Medical: Period from January 2016 to March 2016

2016 FIRST QUARTER (Jan-Mar)

· Operating loss KSEK -3,551 (-2,644)

· Loss per share SEK -0.18 (-0.33)

IMPORTANT EVENTS DURING THE PERIOD

· In March Peptonic Medical received approval to start the planned
clinical Phase 2b study from the Swedish Medical Products Agency.
Previously Peptonic had received approval from the Ethical Vetting
Board.

· The Formulation patent has been approved also in China.Earlier it
has been approved i.a. in Europe and the US.

IMPORTANT EVENTS AFTER THE END OF THE PERIOD

· The Nomination Committee will propose to the Annual General
Meeting on May 19th, that Mr Hans von Celsing be elected as Chairman
of the Board of Peptonic Medical. Present chairman, Ron Long, has
announced that he will not be standing for re-election.

· The 3rdof May the first patients entered Peptonic Medical's
clinical phase 2b study. The aim of the study is to investigate the
effect of Peptonic Medical's product candidate Vagitocin® on vaginal
atrophy in menopausal and post-menopausal women.

From the CEO

During the past few months, focus has been almost entirely on the
preparations of the clinical phase 2b study. We have received the
required approvals from the authorities, the first batches of the
oxytocin gel have been manufactured, the study sites have been
initiated, the study protocol has been presented to the head
clinicians, service agreements with laboratories and other providers
have been signed and advertising for study subjects has started, etc.
Everything has gone according to time plan and budget, which means
that the first subjects were randomised in to the study in the
beginning of this month.

We will carefully monitor the continued patient recruitment and any
feedback from the study sites and study subjects during the coming
months. Results from the main study (gel in glass syringes) are
expected by the end of this year, whereas the results from the
exploratory study (gel in laminated tubes) are expected during Q1
2017.

In collaboration with TEFEN - an international management consulting
firm - a market research project targeting the Vaginal Atrophy (VA)
markets of the USA, the five largest countries in Europe and the
Nordic countries has been concluded. The objectives of this project
were to gain a better understanding of the patient flows, who the
prescribers and main competitors are, the current value of the VA
market, and to develop an interactive valuation model for Vagitocin®.
This project has provided valuable information about the most
important markets and a useful tool for the anticipated out-licensing
negotiations.

The distribution agreement signed in 2009, granting Alium Medical Ltd.
(formerly Pharmarama Ltd.) exclusive distribution rights to
Vagitocin® in the UK and Ireland has been terminated. This means that
Peptonic has regained the right to distribute Vagitocin® in these
territories, either through its own sales force or through a future
partner. In conjunction with the termination, Peptonic Medical
reimbursed Alium Medical for costs incurred for market access
activities.

Stockholm May 17, 2016

Johan Inborr
CEO, Peptonic Medical AB

COMPANY BRIEF

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical
company developing oxytocin based products e.g. for the treatment of
menopausal symptoms, such as vaginal atrophy. Oxytocin has a long
history of safe medical use and offers an alternative to estrogen and
estrogen-like acting compounds for menopausal and postmenopausal
women. Peptonic Medical AB (publ)'s mission is to develop safe and
effective drugs based on oxytocin.

FINANCIAL INFORMATION
Net sales - Currently the company has no net sale.

Costs - Costs for the first quarter were KSEK -3,551 (-2,644).

Result - Loss before tax for the first quarter was KSEK -3,537
(-2,629).

Financial position and liquidity - Liquid assets was KSEK 21,650
(20,338) as of March 31, 2016.

Equity - PEPTONIC medical AB's equity amounted to KSEK 63,975 (52,769)
as of March 31, 2016, resulting in a solidity of 86 (86) percent.

Organization - The average number of employees during the period was 2
(2). At the end of the period the number of employees was 2 (2).

Share - Total numbers of shares in the company amounted to 19,174,412,
as of March 31, 2016.

-----------------------------------------------------------
http://news.cision.com/peptonic-medical/r/period-from-january-2016-to-ma...
http://mb.cision.com/Main/11203/2010237/516413.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.